Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and Pamiparib in Advanced Solid Tumors
NCT02660034Phase 1Completed
- Sponsor
- BeiGene
- Start
- Feb 2016
- Primary completion
- Sep 2020
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label trial of tislelizumab and pamiparib in solid tumor, ovarian cancer, triple-negative breast cancer (TNBC) and 8 more (2 arms), sponsored by BeiGene. Primary endpoints: Number Of Participants Experiencing Adverse Events (AEs), Number Of Participants Experiencing Dose-limiting Toxicity at 21 days and 6 more. Started Feb 2016; status: completed.
02
Drugs
tislelizumabpamiparib
03
Conditions
solid tumorovarian cancertriple-negative breast cancer (TNBC)castration-resistant prostate cancer (CRPC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02660034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02660034.